百奥泰股价涨5.38%，鹏华基金旗下1只基金重仓，持有600股浮盈赚取852元

Group 1 - The core viewpoint of the news is that Baiotai Biopharmaceutical Co., Ltd. has seen a stock price increase of 5.38%, reaching 27.80 yuan per share, with a total market capitalization of 11.511 billion yuan [1] - Baiotai's main business involves the research and development, production of innovative drugs and biosimilars, with the revenue composition being 91.90% from drug sales, 6.55% from licensing, 0.90% from processing, and 0.65% from technical services [1] Group 2 - From the perspective of fund holdings, Penghua Fund has a significant position in Baiotai, with the Penghua Anze Mixed A fund holding 600 shares, accounting for 0.02% of the fund's net value [2] - The Penghua Anze Mixed A fund has a total scale of 13.306 million yuan and has achieved a year-to-date return of 2.53% [2] Group 3 - The fund managers of Penghua Anze Mixed A include Zhu Song, Zhang Jingxian, and Shi Yunchao, with Zhu Song having a tenure of 11 years and 255 days, managing assets totaling 27.86 billion yuan [3] - The best fund return during Zhu Song's tenure is 106.13%, while the worst is 0.86% [3]